Wass JA - Search Results

1

A comparison of lanreotide and octreotide LAR for treatment of acromegaly.

Turner HE, Vadivale A, Keenan J, Wass JA. Turner HE, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 1999 Sep;51(3):275-80. doi: 10.1046/j.1365-2265.1999.00853.x. Clin Endocrinol (Oxf). 1999. PMID: 10469005

2

Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.

Turner HE, Thornton-Jones VA, Wass JA. Turner HE, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31. doi: 10.1111/j.1365-2265.2004.02084.x. Clin Endocrinol (Oxf). 2004. PMID: 15272918

3

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.

Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA. Karavitaki N, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2005 Mar;62(3):282-8. doi: 10.1111/j.1365-2265.2004.02191.x. Clin Endocrinol (Oxf). 2005. PMID: 15730408

4

GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.

Karavitaki N, Warner JT, Marland A, Shine B, Ryan F, Arnold J, Turner HE, Wass JA. Karavitaki N, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2006 May;64(5):556-60. doi: 10.1111/j.1365-2265.2006.02508.x. Clin Endocrinol (Oxf). 2006. PMID: 16649976

5

Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit.

Yap LB, Turner HE, Adams CB, Wass JA. Yap LB, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2002 Jan;56(1):25-31. doi: 10.1046/j.0300-0664.2001.01444.x. Clin Endocrinol (Oxf). 2002. PMID: 11849243

6

Antiangiogenic effects of somatostatin analogues.

García de la Torre N, Wass JA, Turner HE. García de la Torre N, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2002 Oct;57(4):425-41. doi: 10.1046/j.1365-2265.2002.01619.x. Clin Endocrinol (Oxf). 2002. PMID: 12354124 Review.

7

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Bevan JS, et al. Among authors: wass ja. J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63. doi: 10.1210/jc.2001-012012. J Clin Endocrinol Metab. 2002. PMID: 12364434 Clinical Trial.

8

Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.

Bradley KJ, Wass JA, Turner HE. Bradley KJ, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2003 Jan;58(1):59-64. doi: 10.1046/j.1365-2265.2003.01674.x. Clin Endocrinol (Oxf). 2003. PMID: 12519413

9

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.

Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA. Karavitaki N, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5. doi: 10.1111/j.1365-2265.2007.03139.x. Epub 2007 Nov 19. Clin Endocrinol (Oxf). 2008. PMID: 18031313 Clinical Trial.

10

Gonadal function in men with chronic illness.

Turner HE, Wass JA. Turner HE, et al. Among authors: wass ja. Clin Endocrinol (Oxf). 1997 Oct;47(4):379-403. doi: 10.1046/j.1365-2265.1997.2611108.x. Clin Endocrinol (Oxf). 1997. PMID: 9404435 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

422 results

Search Page

Filters